227 related articles for article (PubMed ID: 16283304)
1. Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors.
Bundell CS; Jackaman C; Suhrbier A; Robinson BW; Nelson DJ
Cancer Immunol Immunother; 2006 Aug; 55(8):933-47. PubMed ID: 16283304
[TBL] [Abstract][Full Text] [Related]
2. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
3. Generation of tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide.
Chung SW; Cohen EP; Kim TS
Vaccine; 2004 Jun; 22(20):2547-57. PubMed ID: 15193380
[TBL] [Abstract][Full Text] [Related]
4. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
Seeley BM; Barthel SW; To WC; Kjaergaard J; Shu S; Plautz GE
Otolaryngol Head Neck Surg; 2001 Apr; 124(4):436-41. PubMed ID: 11283503
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo.
Jackaman C; Majewski D; Fox SA; Nowak AK; Nelson DJ
Cancer Immunol Immunother; 2012 Dec; 61(12):2343-56. PubMed ID: 22714286
[TBL] [Abstract][Full Text] [Related]
6. MHC class II presentation of endogenously expressed antigens by transfected dendritic cells.
Diebold SS; Cotten M; Koch N; Zenke M
Gene Ther; 2001 Mar; 8(6):487-93. PubMed ID: 11313828
[TBL] [Abstract][Full Text] [Related]
7. Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis--implications for tumor tolerance.
Robinson BW; Scott BM; Lake RA; Stumbles PA; Nelson DJ; Fisher S; Marzo AL
Clin Cancer Res; 2001 Mar; 7(3 Suppl):811s-817s. PubMed ID: 11300477
[TBL] [Abstract][Full Text] [Related]
8. Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell.
Gao FG; Khammanivong V; Liu WJ; Leggatt GR; Frazer IH; Fernando GJ
Cancer Res; 2002 Nov; 62(22):6438-41. PubMed ID: 12438231
[TBL] [Abstract][Full Text] [Related]
9. High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.
Vierboom MP; Zwaveling S; Bos GMJ ; Ooms M; Krietemeijer GM; Melief CJ; Offringa R
Cancer Res; 2000 Oct; 60(19):5508-13. PubMed ID: 11034095
[TBL] [Abstract][Full Text] [Related]
10. The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus.
Rosato A; Dalla Santa S; Zoso A; Giacomelli S; Milan G; Macino B; Tosello V; Dellabona P; Lollini PL; De Giovanni C; Zanovello P
Cancer Res; 2003 May; 63(9):2158-63. PubMed ID: 12727834
[TBL] [Abstract][Full Text] [Related]
11. Characterization of cloned class I MHC-restricted, CD8+ anti-Meth A cytotoxic T-lymphocytes: recognition of an epitope derived from the Meth A gp110 tumor rejection antigen.
Fassanito MA; Loftus D; De Leo RM; Law LW; Appella E; De Leo AB
Cancer Res; 1994 Aug; 54(16):4424-9. PubMed ID: 7519121
[TBL] [Abstract][Full Text] [Related]
12. In vivo cross-presentation of a soluble protein antigen: kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes.
Nelson D; Bundell C; Robinson B
J Immunol; 2000 Dec; 165(11):6123-32. PubMed ID: 11086045
[TBL] [Abstract][Full Text] [Related]
13. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
[TBL] [Abstract][Full Text] [Related]
14. Enhanced tumor immunogenicity through coupling cytokine expression with antigen presentation.
He X; Tsang TC; Luo P; Zhang T; Harris DT
Cancer Gene Ther; 2003 Sep; 10(9):669-77. PubMed ID: 12944986
[TBL] [Abstract][Full Text] [Related]
15. Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected.
Ramarathinam L; Sarma S; Maric M; Zhao M; Yang G; Chen L; Liu Y
J Immunol; 1995 Dec; 155(11):5323-9. PubMed ID: 7594546
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor.
McAdam AJ; Pulaski BA; Storozynsky E; Yeh KY; Sickel JZ; Frelinger JG; Lord EM
Cell Immunol; 1995 Oct; 165(2):183-92. PubMed ID: 7553882
[TBL] [Abstract][Full Text] [Related]
17. Optimal induction of effector but not memory antitumor cytotoxic T lymphocytes involves direct antigen presentation by the tumor cells.
Guilloux Y; Bai XF; Liu X; Zheng P; Liu Y
Cancer Res; 2001 Feb; 61(3):1107-12. PubMed ID: 11221840
[TBL] [Abstract][Full Text] [Related]
18. Characterization of mouse MAGE-derived H-2Kb-restricted CTL epitopes.
Eggert AO; Andersen MH; Voigt H; Schrama D; Kämpgen E; Straten PT; Becker JC
Eur J Immunol; 2004 Nov; 34(11):3285-90. PubMed ID: 15384049
[TBL] [Abstract][Full Text] [Related]
19. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL.
Nelson DJ; Mukherjee S; Bundell C; Fisher S; van Hagen D; Robinson B
J Immunol; 2001 May; 166(9):5557-66. PubMed ID: 11313395
[TBL] [Abstract][Full Text] [Related]
20. Identification of shared tumor-associated antigen peptides between two spontaneous lung carcinomas.
Mandelboim O; Bar-Haim E; Vadai E; Fridkin M; Eisenbach L
J Immunol; 1997 Dec; 159(12):6030-6. PubMed ID: 9550401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
